- Home
- CGBD vs ABUS Comparison
CGBD vs ABUS Comparison
Compare CGBD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- ABUS
- Stock Information
- Founded
- CGBD 2012
- ABUS N/A
- Country
- CGBD United States
- ABUS United States
- Employees
- CGBD N/A
- ABUS N/A
- Industry
- CGBD Finance: Consumer Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- ABUS Health Care
- Exchange
- CGBD Nasdaq
- ABUS Nasdaq
- Market Cap
- CGBD 825.7M
- ABUS 725.9M
- IPO Year
- CGBD 2017
- ABUS N/A
- Fundamental
- Price
- CGBD $16.67
- ABUS $3.46
- Analyst Decision
- CGBD Hold
- ABUS Strong Buy
- Analyst Count
- CGBD 4
- ABUS 4
- Target Price
- CGBD $16.25
- ABUS $5.50
- AVG Volume (30 Days)
- CGBD 168.9K
- ABUS 837.4K
- Earning Date
- CGBD 11-05-2024
- ABUS 11-06-2024
- Dividend Yield
- CGBD 2.86%
- ABUS N/A
- EPS Growth
- CGBD 29.39
- ABUS N/A
- EPS
- CGBD 1.72
- ABUS N/A
- Revenue
- CGBD $238,921,000.00
- ABUS $6,742,000.00
- Revenue This Year
- CGBD N/A
- ABUS N/A
- Revenue Next Year
- CGBD $5.81
- ABUS N/A
- P/E Ratio
- CGBD $9.64
- ABUS N/A
- Revenue Growth
- CGBD 1.68
- ABUS N/A
- 52 Week Low
- CGBD $14.76
- ABUS $1.79
- 52 Week High
- CGBD $18.74
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- CGBD 48.01
- ABUS 30.63
- Support Level
- CGBD $16.10
- ABUS $3.42
- Resistance Level
- CGBD $16.47
- ABUS $3.81
- Average True Range (ATR)
- CGBD 0.33
- ABUS 0.16
- MACD
- CGBD 0.02
- ABUS -0.04
- Stochastic Oscillator
- CGBD 65.64
- ABUS 7.41
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.